- Home
- MYGN vs AMN Comparison
MYGN vs AMN Comparison
Compare MYGN & AMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- AMN
- Stock Information
- Founded
- MYGN 1991
- AMN 1985
- Country
- MYGN United States
- AMN United States
- Employees
- MYGN N/A
- AMN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AMN Assisted Living Services
- Sector
- MYGN Health Care
- AMN Health Care
- Exchange
- MYGN Nasdaq
- AMN Nasdaq
- Market Cap
- MYGN 744.7M
- AMN 840.0M
- IPO Year
- MYGN 1995
- AMN 2001
- Fundamental
- Price
- MYGN $5.34
- AMN $21.42
- Analyst Decision
- MYGN Hold
- AMN Hold
- Analyst Count
- MYGN 15
- AMN 8
- Target Price
- MYGN $15.14
- AMN $31.92
- AVG Volume (30 Days)
- MYGN 1.3M
- AMN 602.9K
- Earning Date
- MYGN 08-05-2025
- AMN 08-07-2025
- Dividend Yield
- MYGN N/A
- AMN N/A
- EPS Growth
- MYGN N/A
- AMN N/A
- EPS
- MYGN N/A
- AMN N/A
- Revenue
- MYGN $831,300,000.00
- AMN $2,852,436,000.00
- Revenue This Year
- MYGN N/A
- AMN N/A
- Revenue Next Year
- MYGN $6.68
- AMN $2.05
- P/E Ratio
- MYGN N/A
- AMN N/A
- Revenue Growth
- MYGN 7.38
- AMN N/A
- 52 Week Low
- MYGN $3.81
- AMN $17.45
- 52 Week High
- MYGN $29.30
- AMN $70.07
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- AMN 49.43
- Support Level
- MYGN $4.90
- AMN $21.28
- Resistance Level
- MYGN $5.83
- AMN $22.45
- Average True Range (ATR)
- MYGN 0.28
- AMN 0.98
- MACD
- MYGN 0.04
- AMN 0.02
- Stochastic Oscillator
- MYGN 54.21
- AMN 41.93
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About AMN AMN Healthcare Services Inc
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are; nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. A majority of its revenue is generated from the nurse and allied solutions segment which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.